SPEX — Spexis AG Share Price
Last trade - 00:00- CH₣4.40m
- CH₣11.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.25 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.91% | ||
| Return on Equity | -56.91% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 6.55 | 0.01 | 14.28 | n/a | n/a | 12.2 | 2.2 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Directors
- Kuno Sommer NEC (64)
- Gokhan Batur CEO (38)
- Andreas Wallnoefer NVC (60)
- Hernan Levett CFO (45)
- Daniel Obrecht CSO (65)
- Franziska Mueller EXB (38)
- Frank Weber EXB (60)
- Bernard Bollag NED (60)
- Silvio Inderbitzin NED (55)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- November 6th, 1996
- Public Since
- May 15th, 2018
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 67,664,495
- Address
- Hegenheimermattweg 125, ALLSCHWIL, 4123
- Web
- https://spexisbio.com/
- Phone
- +41 615671600
- Contact
- Hernan Levett
- Auditors
- Ernst & Young Ltd
Latest News for SPEX
Upcoming Events for SPEX
Full Year 2023 Spexis AG Earnings Release
Half Year 2024 Spexis AG Earnings Release
Similar to SPEX
Cosmo Pharmaceuticals NV
SIX Swiss Exchange
Dottikon Es Holding AG
SIX Swiss Exchange
Galenica AG
SIX Swiss Exchange
Newron Pharmaceuticals SpA
SIX Swiss Exchange
Novartis AG
SIX Swiss Exchange
FAQ
As of Today at 19:20 UTC, shares in Spexis AG are trading at CH₣0.07. This share price information is delayed by 15 minutes.
Shares in Spexis AG last closed at CH₣0.07 and the price had moved by -80.71% over the past 365 days. In terms of relative price strength the Spexis AG share price has underperformed the FTSE Global All Cap Index by -82.21% over the past year.
The overall consensus recommendation for Spexis AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Spexis AG does not currently pay a dividend.
Spexis AG does not currently pay a dividend.
Spexis AG does not currently pay a dividend.
To buy shares in Spexis AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣0.07, shares in Spexis AG had a market capitalisation of CH₣4.40m.
Here are the trading details for Spexis AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: SPEX
Based on an overall assessment of its quality, value and momentum Spexis AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Spexis AG is CH₣1.80. That is 2669.23% above the last closing price of CH₣0.07.
Analysts covering Spexis AG currently have a consensus Earnings Per Share (EPS) forecast of -CH₣0.13 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spexis AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -70.97%.
As of the last closing price of CH₣0.07, shares in Spexis AG were trading -69.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Spexis AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Spexis AG's management team is headed by:
- Kuno Sommer - NEC
- Gokhan Batur - CEO
- Andreas Wallnoefer - NVC
- Hernan Levett - CFO
- Daniel Obrecht - CSO
- Franziska Mueller - EXB
- Frank Weber - EXB
- Bernard Bollag - NED
- Silvio Inderbitzin - NED